{"entity":{"type":"insider","cik":"0001779990","url":"/insider/0001779990","json_url":"/insider/0001779990.json","name":"HENDERSON MICHAEL THOMAS","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":91,"n_filings":40,"first":"2019-07-03","last":"2026-07-10","span_basis":"filed_date"},"name_variants":[{"name":"HENDERSON MICHAEL THOMAS","source":"filing","n_filings":40,"first_seen":"2019-07-03","last_seen":"2026-07-10"}],"transactions":[{"id":5942691,"accession":"0001104659-26-082758","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-082758","line_url":"/filing/0001104659-26-082758#line-1","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":133.63,"price_display":"133.63","price_state":"stated","total_value":2672600.0,"total_display":"2,672,600.00","total_whole":"2,672,600","shares_owned_after":995987.0,"shares_owned_after_display":"995,987","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-08","filed_date":"2026-07-10","scope":"insider"},{"id":5967563,"accession":"0001636282-26-000084","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-26-000084","line_url":"/filing/0001636282-26-000084#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":68606.0,"shares_owned_after_display":"68,606","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-23","scope":"insider"},{"id":5856064,"accession":"0001104659-26-077426","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-077426","line_url":"/filing/0001104659-26-077426#line-1","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":80000.0,"shares_display":"80,000","price_per_share":132.54,"price_display":"132.54","price_state":"stated","total_value":10603200.0,"total_display":"10,603,200.00","total_whole":"10,603,200","shares_owned_after":1015987.0,"shares_owned_after_display":"1,015,987","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-24","scope":"insider"},{"id":5821176,"accession":"0001104659-26-073567","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-26-073567","line_url":"/filing/0001104659-26-073567","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":83.381083,"price_display":"83.38","price_state":"stated","total_value":1667621.66,"total_display":"1,667,621.66","total_whole":"1,667,622","shares_owned_after":1101563.0,"shares_owned_after_display":"1,101,563","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-10","filed_date":"2026-06-12","scope":"insider","n_lines":6},{"id":5928401,"accession":"0001104659-26-062867","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-062867","line_url":"/filing/0001104659-26-062867","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":82.0855365,"price_display":"82.09","price_state":"stated","total_value":1641710.73,"total_display":"1,641,710.73","total_whole":"1,641,711","shares_owned_after":1117328.0,"shares_owned_after_display":"1,117,328","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-13","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":5802805,"accession":"0001636282-26-000053","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001636282-26-000053","line_url":"/filing/0001636282-26-000053","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":80000.0,"shares_display":"80,000","price_per_share":74.400630375,"price_display":"74.40","price_state":"stated","total_value":5952050.43,"total_display":"5,952,050.43","total_whole":"5,952,050","shares_owned_after":132689.0,"shares_owned_after_display":"132,689","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-08","filed_date":"2026-05-08","scope":"insider","n_lines":4},{"id":6226456,"accession":"0001104659-26-042155","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-042155","line_url":"/filing/0001104659-26-042155","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":82.5832,"price_display":"82.58","price_state":"stated","total_value":1651664.0,"total_display":"1,651,664.00","total_whole":"1,651,664","shares_owned_after":1135187.0,"shares_owned_after_display":"1,135,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-08","filed_date":"2026-04-10","scope":"insider","n_lines":3},{"id":5928231,"accession":"0001104659-26-027802","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-027802","line_url":"/filing/0001104659-26-027802","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":74.780226,"price_display":"74.78","price_state":"stated","total_value":1495604.52,"total_display":"1,495,604.52","total_whole":"1,495,605","shares_owned_after":1164624.0,"shares_owned_after_display":"1,164,624","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-11","filed_date":"2026-03-13","scope":"insider","n_lines":3},{"id":5992984,"accession":"0001104659-26-015453","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-015453","line_url":"/filing/0001104659-26-015453","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":63.347646,"price_display":"63.35","price_state":"stated","total_value":1266952.92,"total_display":"1,266,952.92","total_whole":"1,266,953","shares_owned_after":1181493.0,"shares_owned_after_display":"1,181,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-11","filed_date":"2026-02-13","scope":"insider","n_lines":3},{"id":5902277,"accession":"0001104659-26-004659","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-26-004659","line_url":"/filing/0001104659-26-004659","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":81.107956,"price_display":"81.11","price_state":"stated","total_value":1622159.12,"total_display":"1,622,159.12","total_whole":"1,622,159","shares_owned_after":1203071.0,"shares_owned_after_display":"1,203,071","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-14","filed_date":"2026-01-16","scope":"insider","n_lines":6},{"id":4392889,"accession":"0001104659-25-120758","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-25-120758","line_url":"/filing/0001104659-25-120758","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":75.3828275,"price_display":"75.38","price_state":"stated","total_value":1507656.55,"total_display":"1,507,656.55","total_whole":"1,507,657","shares_owned_after":1213547.0,"shares_owned_after_display":"1,213,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-10","filed_date":"2025-12-12","scope":"insider","n_lines":3},{"id":5129758,"accession":"0001104659-25-118983","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-118983","line_url":"/filing/0001104659-25-118983#line-1","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":75.01,"price_display":"75.01","price_state":"stated","total_value":3000400.0,"total_display":"3,000,400.00","total_whole":"3,000,400","shares_owned_after":1232987.0,"shares_owned_after_display":"1,232,987","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-04","filed_date":"2025-12-05","scope":"insider"},{"id":4764782,"accession":"0001104659-25-111626","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-25-111626","line_url":"/filing/0001104659-25-111626","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":63.011805,"price_display":"63.01","price_state":"stated","total_value":1260236.1,"total_display":"1,260,236.10","total_whole":"1,260,236","shares_owned_after":1274873.0,"shares_owned_after_display":"1,274,873","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-13","filed_date":"2025-11-13","scope":"insider","n_lines":4},{"id":4469123,"accession":"0001104659-25-021861","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-021861","line_url":"/filing/0001104659-25-021861","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":30.151136,"price_display":"30.15","price_state":"stated","total_value":301511.36,"total_display":"301,511.36","total_whole":"301,511","shares_owned_after":1295661.0,"shares_owned_after_display":"1,295,661","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider","n_lines":2},{"id":4850485,"accession":"0001104659-25-010642","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-010642","line_url":"/filing/0001104659-25-010642#line-1","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":40.58,"price_display":"40.58","price_state":"stated","total_value":608700.0,"total_display":"608,700.00","total_whole":"608,700","shares_owned_after":1302987.0,"shares_owned_after_display":"1,302,987","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-05","filed_date":"2025-02-07","scope":"insider"},{"id":5128219,"accession":"0001104659-25-002688","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-002688","line_url":"/filing/0001104659-25-002688","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":48.846192,"price_display":"48.85","price_state":"stated","total_value":732692.88,"total_display":"732,692.88","total_whole":"732,693","shares_owned_after":1312355.0,"shares_owned_after_display":"1,312,355","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-08","filed_date":"2025-01-10","scope":"insider","n_lines":2},{"id":2779689,"accession":"0001104659-24-126394","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-126394","line_url":"/filing/0001104659-24-126394","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":46.576912,"price_display":"46.58","price_state":"stated","total_value":698653.68,"total_display":"698,653.68","total_whole":"698,654","shares_owned_after":1326159.0,"shares_owned_after_display":"1,326,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-04","filed_date":"2024-12-06","scope":"insider","n_lines":2},{"id":2238451,"accession":"0001104659-24-116024","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-116024","line_url":"/filing/0001104659-24-116024","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":59.221333333333334,"price_display":"59.22","price_state":"stated","total_value":888320.0,"total_display":"888,320.00","total_whole":"888,320","shares_owned_after":1340487.0,"shares_owned_after_display":"1,340,487","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-06","filed_date":"2024-11-08","scope":"insider","n_lines":2},{"id":2538330,"accession":"0001104659-24-106364","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-106364","line_url":"/filing/0001104659-24-106364","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":56.232676,"price_display":"56.23","price_state":"stated","total_value":2249307.04,"total_display":"2,249,307.04","total_whole":"2,249,307","shares_owned_after":1364199.0,"shares_owned_after_display":"1,364,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-02","filed_date":"2024-10-04","scope":"insider","n_lines":2},{"id":2538170,"accession":"0001104659-24-097866","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-097866","line_url":"/filing/0001104659-24-097866#line-2","is_derivative":false,"issuer_cik":"0001779990","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001779990","owner_cik":"0001779990","owner_name":"HENDERSON MICHAEL THOMAS","owner_display_name":"HENDERSON MICHAEL THOMAS","owner_url":"/insider/0001779990","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25641.0,"shares_display":"25,641","price_per_share":47.28,"price_display":"47.28","price_state":"stated","total_value":1212306.48,"total_display":"1,212,306.48","total_whole":"1,212,306","shares_owned_after":1408846.0,"shares_owned_after_display":"1,408,846","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-04","filed_date":"2024-09-06","scope":"insider"}],"collapsed":true,"next_cursor":"2024-09-04|2538170","ledger_fault":false,"count":{"value":91,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":90,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":91},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001974640","name":"Apogee Therapeutics, Inc.","url":"/issuer/0001974640","role":"Director, Officer (Chief Executive Officer)","n_filings":20,"first_seen":"2024-07-05","last_seen":"2026-07-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Spyre Therapeutics, Inc.","url":"/issuer/0001636282","role":"Director","n_filings":2,"first_seen":"2026-05-08","last_seen":"2026-06-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001743881","name":"BridgeBio Pharma, Inc.","url":"/issuer/0001743881","role":"Officer (Chief Business Officer)","n_filings":18,"first_seen":"2019-07-03","last_seen":"2020-12-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001779990","retrieved_at":"2026-08-22T17:37:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}